Navigation Links
Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
Date:9/11/2013

SCHAUMBURG, Ill. and SOPHIA ANTIPOLIS, France, Sept. 11, 2013 /PRNewswire/ -- Jeannette R. Jakus, MD, MBA, has been selected as the 2013 recipient of the American Academy of Dermatology Translational Biotechnology Fellowship, a partnership of the American Academy of Dermatology and Galderma Research & Development, SNC.

As part of the fellowship, Dr. Jakus will work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis, France, beginning in fall 2013. Sophia Antipolis is the largest corporate-funded facility in the world dedicated to dermatology.

A graduate of Jefferson Medical College, Philadelphia, Dr. Jakus has completed a residency in dermatology and a fellowship in pediatric dermatology at SUNY Downstate Medical Center, Brooklyn, N.Y., and a residency in pediatrics at Mount Sinai Medical Center, New York, N.Y. She also has a master's of business administration from Columbia Business School, New York, N.Y.

The application for the fall 2014 Translational Biotechnology Fellowship is available at www.aad.org/biotechfellowship. Applications are due by October 15, 2013. The 2014 recipient will be notified in December 2013. Preference will be given to candidates who are in their last year of residency in an accredited American College of Graduate Medical Education dermatology residency program. Candidates must be a physician member of the Academy who will have satisfactorily completed a residency no more than three years before the planned start date. The selected candidate will receive a stipend to cover his or her costs during the term of the fellowship.

About the American Academy of Dermatology

Celebrating 75 years of promoting skin, hair and nail health
Headquartered in Schaumburg, Ill., the American Academy of Dermatology (Academy), founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 17,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, contact the Academy at 1-888-462-DERM (3376) or www.aad.org. Follow the Academy on Facebook (American Academy of Dermatology) or Twitter (@AADskin).

About Galderma

A world leading medical company exclusively focused on dermatology

Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 33 wholly-owned affiliates with a worldwide network of distributors and more than 5,000 employees. Galderma's extensive product portfolio is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.

With approximately 20% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world's leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.

Strategic brands include Epiduo®, Oracea®, Mirvaso®, Clobex®, Differin®, Rozex®/MetroGel®, Silkis®/Vectical®, Tri-Luma®, Loceryl®, Cetaphil®, Metvix®, Azzalure®, Restylane® and Emervel®.

For more information, please visit www.galderma.com

About Sophia Antipolis: the world's largest R&D center specialized in dermatology

Galderma's five R&D centers are located in France, Sweden, Switzerland, the United States and Japan and are playing a key role in the discovering and developing of innovative medical solutions for the global dermatology market. Located in southeast France, Galderma's Sophia Antipolis facility is the largest laboratory in the world dedicated exclusively to dermatology. This state-of-the-art center is the birthplace of the adapalene molecule, an active ingredient in Differin® Gel and Epiduo® Gel. Five hundred scientists and support staff work at the center which hosts all of Galderma's in-house research, preclinical and core development (clinical, pharmaceutical and biometric) activities. Since its opening at the end of 2006, this 270,000 sq. feet facility accommodates our scientists with expertise ranging from genomics to proteomics, from high throughput technologies such as screening, chemistry and toxicogenomics to clinical activities in early and full development.

  • With 270,000 sq. feet, Sophia Antipolis, France, is the largest R&D center dedicated to dermatology in the world
  • 11,000 molecules screened since 1981
  • 20 projects in early and full development
  • 6500 patent applications and patents have been filed since 1981.
  • 57 new patents were registered in 2012. Galderma is the leader in filing patents in dermatology.
  • 600 scientists
  • 1,700 scientific publications in 2012
  • ISO 14001 and OHSAS 18001 certifications
  • Compliant with Good Laboratory Practices, Good Manufacturing Practices and Good Clinical Practices

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


'/>"/>
SOURCE Galderma Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
2. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
3. Carolina Piedmont Capital Awarded VOSB Certification
4. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
5. Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
6. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
7. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
8. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
9. All Time Medical awarded a Google Trusted Store badge.
10. Dynamic Healthcare Services Awarded Two Oxygen Equipment Competitive Bidding Contracts
11. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
Breaking Medicine Technology:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning services to communities in east Texas, is launching a regional ... Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... The ... communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to ... husband. , In early June of this year, Christina and her children returned from ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over ... in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for ... aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded ...
Breaking Medicine News(10 mins):